Valneva recently received the greenlight for IXCHIQ by the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya vaccine.
Valneva is pushing forward with its live-attenuated, single-shot vaccine candidate, VLA1553, for chikungunya, a mosquito-borne viral disease for which there are no preventive vaccines or effective treatments available.
Valneva has been awarded up to £20m ($27m) in R&D funding from Scottish Enterprise: which will be used to revive its plans to increase vaccine manufacturing in Scotland.
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.
Vaccine company Valneva has announced positive Phase 3 pivotal results for its single-shot chikungunya vaccine. “We are a step closer to addressing this major, growing and unmet public health threat,” says the company.
Vaccine company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA).